계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Amplo Biotechnology
company
About
Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
Highlights
Details
- Last Funding Type
- Grant
- Industries
- Biotechnology,Health Care,Neuroscience,Therapeutics
- Founded date
- Jan 1, 2019
- Operating Status
- Active
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
Amplo Biotechnology has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Oct 6, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 6, 2021 | Grant | — | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Amplo Biotechnology is funded by 1 investors.
National Institutes of Health (NIH)
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
